BPMC
Blueprint Medicines Corporation
129.46
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 48.43% | |
| 1y | 13.20% |
129.30
day range
129.55
52 week range
| Open | Prev Close | 129.46 | Low | 129.30 | High | 129.55 | Mkt Cap | N/A | |
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -137.72 |
| Beta | 0.83 | Short Ratio | 0.62 | Inst. Own | 109.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 130.29 |
| Income Statement | |||
| Total Revenue | 149.41M | ||
| Revenues (USD) | 149.41M | ||
| Cost of Revenue | 2.80M | ||
| Gross Profit | 146.61M | ||
| Operating Expenses | 187.70M | ||
| Research and Development Expense | 91.89M | ||
| Selling, General and Administrative Expense | 95.81M | ||
| Operating Income | -41.09M | ||
| Interest Expense | 8.13M | ||
| Income Tax Expense | 789.00K | ||
| Net Income | 496.00K | ||
| Net Income Common Stock | 496.00K | ||
| Net Income Common Stock (USD) | 496.00K | ||
| Consolidated Income | 496.00K | ||
| Earnings per Basic Share | 0.01 | ||
| Earnings per Basic Share (USD) | 0.01 | ||
| Earnings per Diluted Share | 0.01 | ||
| Earning Before Interest & Taxes (EBIT) | 9.41M | ||
| Earning Before Interest & Taxes (USD) | 9.41M | ||
| Weighted Average Shares | 64.10M | ||
| Weighted Average Shares Diluted | 66.53M | ||
| Balance Sheet | |||
| Cash and Equivalents | 134.09M | ||
| Cash and Equivalents (USD) | 134.09M | ||
| Investments | 777.54M | ||
| Investments Current | 453.99M | ||
| Investments Non-Current | 323.55M | ||
| Trade and Non-Trade Receivables | 79.80M | ||
| Current Assets | 702.07M | ||
| Property, Plant & Equipment Net | 97.66M | ||
| Total Assets | 1.20B | ||
| Debt Current | 125.45M | ||
| Total Debt | 713.33M | ||
| Current Liabilities | 250.58M | ||
| Debt Non-Current | 587.88M | ||
| Total Liabilities | 853.47M | ||
| Accumulated Retained Earnings (Deficit) | -2.41B | ||
| Accumulated Other Comprehensive Income | -3.24M | ||
| Shareholders Equity | 342.13M | ||
| Shareholders Equity (USD) | 342.13M | ||
| Assets Non-Current | 493.54M | ||
| Total Debt (USD) | 713.33M | ||
| Deferred Revenue | 10.32M | ||
| Inventory | 12.95M | ||
| Liabilities Non-Current | 602.89M | ||
| Trade and Non-Trade Payables | 800.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 7.05M | ||
| Net Cash Flow from Financing | 9.19M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 19.79M | ||
| Capital Expenditure | -1.83M | ||
| Issuance (Purchase) of Equity Shares | 13.30M | ||
| Issuance (Repayment) of Debt Securities | -4.11M | ||
| Net Cash Flow from Investing | 65.08M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 66.91M | ||
| Net Cash Flow from Operations | -54.48M | ||
| Effect of Exchange Rate Changes on Cash | 661.00K | ||
| Share Based Compensation | 29.06M | ||